Compounds and methods for delivery of prostacyclin analogs

Details Compounds and methods for delivery of prostacyclin analogs Compounds and methods for delivery of prostacyclin analogs

2006-11-22

2009-06-09

Saeed, Kamal (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S260000

Reexamination Certificate

active

07544713

ABSTRACT:
This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

REFERENCES:
patent: 4306075 (1981-12-01), Aristoff
patent: 4490537 (1984-12-01), Johnson
patent: 4499085 (1985-02-01), Masuda
patent: 5153222 (1992-10-01), Tadepalli et al.
patent: 5234953 (1993-08-01), Crow et al.
patent: 5814301 (1998-09-01), Klopp et al.
patent: 6054486 (2000-04-01), Crow et al.
patent: 6171786 (2001-01-01), Shtil et al.
patent: 6441245 (2002-08-01), Moriarty et al.
patent: 6451815 (2002-09-01), Hwang et al.
patent: 6469022 (2002-10-01), Schellens
patent: 6521212 (2003-02-01), Cloutier et al.
patent: 6528688 (2003-03-01), Moriarty et al.
patent: 2005/0085540 (2005-04-01), Phares et al.
patent: 2005/0101608 (2005-05-01), Santel
patent: 2005/0282901 (2005-12-01), Phares et al.
patent: 2007/0078095 (2007-04-01), Phares et al.
patent: 2007/0078182 (2007-04-01), Phares et al.
patent: 0 159 784 (1985-10-01), None
patent: 2 070 596 (1981-06-01), None
patent: WO 99/25357 (1999-05-01), None
patent: WO 00/57701 (2000-10-01), None
patent: WO 03/049676 (2003-06-01), None
patent: WO 2005/007081 (2005-01-01), None
patent: WO 2005/058303 (2005-06-01), None
U.S. Appl. No. 60/472,407, filed May 22, 2003, Phares et al.
Remodulin® Product Information brochure, United Therapeutics Corporation, approved by FDA for marketing on May 21, 2002, 13 pages.
Advisory Action mailed Mar. 24, 2008 in copending related U.S. Appl. No. 11/603,219, 3 pgs.
Belch et al., “Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1Prodrug, in Patients With Intermittent Claudication,” Circulation, The American Heart Association, Inc., vol. 95, No. 9, May 1997, pp. 2298-2301.
Okuda et al., “Acute Effect of Beraprost Sodium on Lower Limb Circulation in Patients with Non-Insulin-Dependent Diabetes Mellitus-Evaluation by Color Doppler Ultrasonography and Laser Cutaneous Blood Flowmetry,” Prostaglandins, Elsevier, vol. 52, Nov. 1996, pp. 375-384.
Patterson et al., “Acute Hemodynamic Effects of the Prostacyclin Analog 15AU81 in Service Congestive Heart Failure,” The American Journal of Cardiology, vol. 75, Jan. 19, 1995, pp. 26A-33A.
Mohler, “Clinical Manifestations of Claudication,” Up To Date, Inc., Sep. 30, 1996, pp. 1-4.
Mohler, “Medical Management of Claudication,” Up To Date, Inc., Mar. 31, 1997, pp. 1-6.
J. C. Lee et al., “Efficient In Situ Esterification of Carboxylic Acids Using Cesium Carbonate,” Organic Preparations and Procedures International, vol. 28, No. 4, Aug. 1996, pp. 480-483.
J. Mann et al., Organic Syntheses, John Wiley & Sons, Inc., vol. 75, 1998, pp. 139-145.
A. Hassner et al., “Direct Room Temperature Esterification of Carboxylic Acids” Tetrahedron Letters, Perganon Press Ltd., vol. 46, 1978, pp. 4475-4478.

Affiliated with

Also associated with

Rating

Compounds and methods for delivery of prostacyclin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for delivery of prostacyclin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for delivery of prostacyclin analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4125817